Title:
COMPOSITIONS AND METHODS FOR REDUCING OCULAR NEOVASCULARIZATION
Document Type and Number:
WIPO Patent Application WO/2017/218981
Kind Code:
A3
Abstract:
The present disclosure provides pharmaceutical compositions and methods thereof for the prevention or treatment of ocular neovascularization, such as AMD, in a subject, by administering to the subject a pharmaceutical composition comprising a rAAV vector having a nucleic acid sequence that encodes an anti-VEGF agent.
Inventors:
BLUMENKRANZ MARK (US)
GASMI MEHDI (US)
GASMI MEHDI (US)
Application Number:
PCT/US2017/038012
Publication Date:
February 15, 2018
Filing Date:
June 16, 2017
Export Citation:
Assignee:
ADVERUM BIOTECHNOLOGIES INC (US)
International Classes:
C12N15/09; A61F9/008; A61K38/17; C07K14/005; C07K14/705; C12N15/86; C12N15/861
Foreign References:
| US20140294771A1 | 2014-10-02 | |||
| US20150259395A1 | 2015-09-17 | |||
| US20140242031A1 | 2014-08-28 | |||
| US20110200530A1 | 2011-08-18 |
Other References:
NORK, TM ET AL.: "Prevention of Experimental Choroidal Neovascularization and Resolution of Active Lesions by VEGF Trap in Nonhuman Primates", ARCHIVES OF OPHTHALMOLOGY, vol. 129, no. 8, August 2011 (2011-08-01), pages 1042 - 1052, XP055138977, DOI: doi:10.1001/archophthalmol.2011.210
ANONYMOUS: "Application for inclusion in the WHO Essential Medicines List, Section 21 Ophthalmological Preparations Ranibizumab (Lucentis(R)) - Addition", NOVARTIS, 28 November 2014 (2014-11-28), pages 42, XP055600842
COSTA, RA ET AL.: "Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 47, no. 10, October 2006 (2006-10-01), pages 4569 - 4578, XP055600846, ISSN: 1552-5783, DOI: 10.1167/iovs.06-0433
ANONYMOUS: "Application for inclusion in the WHO Essential Medicines List, Section 21 Ophthalmological Preparations Ranibizumab (Lucentis(R)) - Addition", NOVARTIS, 28 November 2014 (2014-11-28), pages 42, XP055600842
COSTA, RA ET AL.: "Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 47, no. 10, October 2006 (2006-10-01), pages 4569 - 4578, XP055600846, ISSN: 1552-5783, DOI: 10.1167/iovs.06-0433
Attorney, Agent or Firm:
YIN, Eva F. et al. (US)
Download PDF:
Previous Patent: GOLF CLUB HEAD HAVING A MAGNETIC ADJUSTABLE WEIGHTING SYSTEM
Next Patent: ON-DEMAND, PORTABLE CONVECTION VAPORIZER
Next Patent: ON-DEMAND, PORTABLE CONVECTION VAPORIZER